Zelluna ASA: New share capital registered

08 Dec 2025 13:52 CET

Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange
announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding
the successful private placement of 5,500,000 new shares (the "Private
Placement"), divided on a first tranche of 3,729,774 new shares and a second
tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new
shares in the retail offering carried out via the PrimaryBid platform.

The share capital increase pertaining to the issuance of the 1,770,226 new
shares in Tranche 2 has now been registered with the Norwegian Register of
Business Enterprises. The Company's new share capital is NOK 26,269,801 divided
into 26,269,801 shares, each with a par value of NOK 1.

For further information, please contact:

Namir Hassan, CEO, Zelluna ASA
Email: namir.hassan@zelluna.com
(https://www.globenewswire.com/Tracker?data=Z8lLmV-
B1LwB9B24FA19vFGXbMF1uWuib96CE8rRZizu90Na0VH2EMuvz0ZT8R_M3cGZvcz7cwsWR7BQXKOGGup
zjLAZA3udqBHb-dOQPqaJliih1_RADUlCCR7Hs9ov)
Phone: +44 7720 687608

Hans Vassgård Eid, CFO, Zelluna ASA
Email: hans.eid@zelluna.com
(https://www.globenewswire.com/Tracker?data=xw_BegYpiBk6hexlBFgOsk7tj2DC2GZ9wD-
xUL0RvSOAFKyBsXJCyN1-
yeYF_y4PiN7qNCFrqSFIFzf4Oy78pFiEzLGlsgS23tV0HELOjUoSe5eLjAVVxGWn_gS6AJdD)
Phone: +47 482 48632

About Zelluna ASA

Zelluna ASA (OSE: ZLNA) is a biotechnology company pioneering the development of
allogeneic 'off-the-shelf' T Cell Receptor-based Natural Killer (TCR-NK) cells
for the treatment of cancer. The company's platform combines the innate killing
power of NK cells with the precision targeting of TCRs, designed to address the
limitations of current cell therapies, particularly in solid tumours. Zelluna's
proprietary manufacturing process enables scalable, cost-effective production of
TCR-NK cell therapies, with potential for broad patient accessibility. The
company's lead program, ZI-MA4-1, targets the MAGE-A4 tumour antigen and is
expected to enter clinical trials in 2026. Zelluna is headquartered in Oslo,
Norway.

More information:
Access the news on Oslo Bors NewsWeb site